Success examples
[3H]UR-JG102-A Radiolabeled Cyclic Peptide with High Affinity and Excellent Selectivity for the Neuropeptide Y Y4 Receptor

Gleixner J., Gattor A. O., Humphrys L. J., Brunner T., Keller M.

J Med Chem. 2023, 66(19):13788-13808.

NPY2R Antagonist
DOI
PubMed
Success examples
SGLT2 inhibitors prevent LPS-induced M1 macrophage polarization and alleviate inflammatory bowel disease by downregulating NHE1 expression

Kim Y. J., Jin J., Kim D-H., Kim D., Lee Y. M., Byun J-K., Choi Y-K., Park K-G.

Inflamm Res. 2023, 72(10-11):1981-1997.

NHE1 inhibitor
DOI
PubMed
Success examples
Focal Adhesion Kinase Binds to the HPV E2 Protein to Regulate Initial Replication after Infection

Jose L., Gonzalez J., Kessinger E., Androphy E. J., DeSmet M.

Pathogens 2023, 12(10), 1203.

PTK2 PROTAC
DOI
General literature
Developing a Kinase Chemogenomic Set: Facilitating Investigation into Kinase Biology by Linking Phenotypes to Targets

Wells C. I., Drewry D. H.

Methods Mol Biol. 2023, 2706:11-24.

DOI
PubMed
Success examples
Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation

Mader M. M., Rudolph J., Hartung I. V., Uehling D., Workman P., Zuercher W.

Cancer Discov. 2023, 13(10):2150-2165.

SMARCA2 PROTAC
DOI
PubMed
Success examples
Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity

Koide E., Mohardt M. L., Doctor Z. M., Yang A., Hao M., Donovan K. A., Kuismi C. C., Nelson A. J., Abell K., Aguiar M., Che J., Stokes M. P., Zhang T., Aguirre A. J., Fischer E. S., Gray N. S., Jiang B., Nabet B.

Chembiochem. 2023, 24(19):e202300141.

PTK2 PROTAC PTK2 PROTAC
DOI
PubMed